APX601 / Pyxis Oncology - LARVOL DELTA

Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "'In the third quarter of 2022, we took important steps to build our business as a publicly listed biopharmaceutical company and continued to advance our lead program, sotigalimab'...In preclinical models, APX601 depletes and inactivates TNFR2-expressing Tregs, reverses myeloid-mediated T-cell suppression and directly kills TNFR2-expressing tumor cells. APX601 shows potent anti-tumor activity in tumor models...APX601 is IND-ready and Apexigen plans to advance APX601 into a Phase 1/2 clinical trial for the treatment of multiple tumor indications of unmet medical need when the company secures adequate financing; APX801 is currently at the pre-clinical stage and Apexigen plans to advance APX801 into IND-enabling studies when the company secures additional financing...Apexigen reported a net loss of $8.5 million, or $0.41 per common share, for the third quarter of 2022 compared to $7.3 million, or $0.40 per common share, for the same period in 2021."

Commercial • New P1/2 trial • Preclinical • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Melanoma • Oncology • Sarcoma • Skin Cancer • Soft Tissue Sarcoma • Solid Tumor

Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB Platform (GlobeNewswire) - "The company will discuss lead asset sotigalimab’s Phase 2 development program with a focus on melanoma, esophageal/GEJ cancer and sarcoma indications, its positioning in the competitive landscape, key data to date and upcoming milestones. The company will also highlight its promising preclinical program APX601, an anti-TNFR2 antagonist antibody."

Clinical • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Melanoma • Oncology • Sarcoma • Solid Tumor

[VIRTUAL] APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression (AACR 2021) - "APX601 was evaluated in a repeat dose range finding toxicology study in monkeys and demonstrated a good safety profile when administered up to 100mg/kg. These data strongly support the development of APX601 as a novel therapeutic approach for reversing tumor immune suppression and for the treatment solid tumors."

Late-breaking abstract • Oncology • Solid Tumor • TNFRSF1B

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 (PRNewswire) - "Apexigen...announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021...The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021."

Preclinical • Oncology

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 (PRNewswire) - “Apexigen, Inc…announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021. Details are as follows: Title of Presentation: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression; Title of Presentation: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177).”

Preclinical • Oncology

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting (PRNewswire) - “Apexigen, Inc…announced two upcoming poster presentations at the 35th Society for Immunotherapy of Cancer (SITC) Annual Meeting, to be held November 9-14, 2020.”

Preclinical • Oncology

[VIRTUAL] APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy (SITC 2020) - "Our data support the further development of APX601, a promising immunotherapeutic antibody with multiple potential mechanisms of action, for the treatment of a variety of solid tumors. Ethics Approval Healthy human blood samples were obtained from Stanford Blood Center (Palo Alto, CA) from consenting donors under an approved protocol."

IO Biomarker • Oncology • Solid Tumor • TNFRSF1B

[VIRTUAL] APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy (SITC 2020) - "Our data support the further development of APX601, a promising immunotherapeutic antibody with multiple potential mechanisms of action, for the treatment of a variety of solid tumors. Ethics Approval Healthy human blood samples were obtained from Stanford Blood Center (Palo Alto, CA) from consenting donors under an approved protocol."

IO Biomarker • Oncology • Solid Tumor • TNFRSF1B